Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 3/2010

01-09-2010 | Nephrology - Editorial

Statin use in patients with chronic kidney disease stages 2–4: targeting beyond improved mortality rates

Authors: Kosmas I. Paraskevas, Alexandros A. Tzovaras, Vassilios Stathopoulos, Dimitri P. Mikhailidis

Published in: International Urology and Nephrology | Issue 3/2010

Login to get access

Excerpt

The well-designed study by Neves et al. [1] showed that statin and/or vitamin D non-use were independent risk factors of mortality (p = 0.005) in their cohort of patients (n = 95) with chronic kidney disease (CKD) stages 4 and 5 (mean estimated glomerular filtration rate [eGFR] = 16.1 ml/min/1.73 m2). After a mean follow-up of 24.1 ± 9.8 months, all patients receiving both statins and vitamin D were alive (18 of 18 patients; 100%). In contrast, only 24 of the 43 patients (56.4%) receiving neither a statin nor vitamin D were alive at the end of the study [1]. …
Literature
1.
2.
Molitch ME (2006) Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 1:1090–1099CrossRefPubMed
3.
Banerjee D, Contreras G, Jaraba I et al (2009) Chronic kidney disease stages 3–5 and cardiovascular disease in the veterans affairs population. Int Urol Nephrol 41:443–451CrossRefPubMed
4.
Meyer KB, Levey AS (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol 9(12 Suppl):S31–S42PubMed
5.
Tonelli M, Isles C, Curhan GC et al (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557–1563CrossRefPubMed
6.
Sacks FM, Pfeffer MA, Moye LA et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001–1009CrossRefPubMed
7.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357CrossRef
8.
Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301–1307CrossRefPubMed
9.
Wanner C, Krane V, März W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248CrossRefPubMed
10.
Farbakhsh K, Kasiske BL (2005) Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am 89:689–699CrossRefPubMed
11.
Paraskevas KI (2008) Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. Int Urol Nephrol 40:165–170CrossRefPubMed
12.
Gelev S, Spasovski G, Dzikova S et al (2008) Vascular calcification and atherosclerosis in hemodialysis patients: what can we learn from the routine clinical practice? Int Urol Nephrol 40:763–770CrossRefPubMed
13.
Turgut F, Kanbay M, Metin MR et al (2008) Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 40:1075–1082CrossRefPubMed
14.
Civilibal M, Oflaz H, Caliskan S et al (2009) Left ventricular systolic and diastolic function and carotid intima—media thickness in pediatric dialysis patients. Int Urol Nephrol 41:401–408CrossRefPubMed
15.
Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP, GREACE Study Collaborative Group (2003) Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 19:615–617CrossRefPubMed
16.
Athyros VG, Mikhailidis DP, Papageorgiou AA et al (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:328–334CrossRef
17.
Athyros VG, Elisaf M, Papageorgiou AA, GREACE Study Collaborative Group et al (2004) Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43:589–599CrossRefPubMed
18.
Rysz J, Aronow WS, Stolarek RS et al (2009) Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 13:541–550CrossRefPubMed
19.
Youssef F, Gupta P, Seifalian AM et al (2004) The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 55:53–62CrossRefPubMed
20.
Alnaeb ME, Youssef F, Mikhailidis DP et al (2006) Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology 57:65–71CrossRefPubMed
Metadata
Title
Statin use in patients with chronic kidney disease stages 2–4: targeting beyond improved mortality rates
Authors
Kosmas I. Paraskevas
Alexandros A. Tzovaras
Vassilios Stathopoulos
Dimitri P. Mikhailidis
Publication date
01-09-2010
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2010
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9677-z

Other articles of this Issue 3/2010

International Urology and Nephrology 3/2010 Go to the issue

Nephrology – Translational Section

High mobility group box protein-1 crossing cell borders may incite an inflammatory “tornado” in renal disease

Urology – Editorial

Editorial comment: Hippocratic Oath and plagiarism

Nephrology – Editorial

Geriatric renal palliative care is coming of age

Nephrology - Original Paper

Postnatal assessment of growth, nutrition, and urinary tract infections of infants with antenatally detected hydronephrosis

Urology - Original Paper

The use of seromuscular tapered ileal tube in ureteral replacement: an experimental model

Nephrology - Case Report

Late diagnosis of primary hyperoxaluria after failed kidney transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits